Annexon proclaims Phase 3 win for complement inhibitor in Guillain-Barré Syndrome

Annexon Biosciences reported new Phase 3 data for its Guillain-Barré Syndrome (GBS) drug Tuesday morning, saying the low dose achieved the trial’s primary endpoint. …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SphingoTec Closes €5M Series C to Accelerate Market Development and Financial Growth with Innovative Biomarkers – Biotech Investments

Issuer: SphingoTec GmbH / Key word(s): Financing/Investment 08.08.2024 / 10:00 CET/CEST The issuer is solely responsible for the content of this announcement. SphingoTec GmbH has

August 9, 2024

Opinion | Creating a ‘Healthier’ Health System: How Hard Could It Be?

David Nash is the Founding Dean Emeritus and Dr. Raymond C. and Doris N. Grandon Professor of Health Policy at the Jefferson College of Population

September 28, 2024

Navigating market access in Sweden – Pharmaceutical Technology

Stockholm, Sweden. Demand for pharmaceuticals is growing in Sweden and healthcare expenditure is increasing, with GlobalData expecting 2.9% growth in 2023 and a 4.4% rise

August 8, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.